Drug Trial Radar · NCT07723469
Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Oct 2034
Study completion Oct 2034
Sponsor
- Lead sponsor
- SURGE TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient \[API\]: ketorolac) administered intraoperatively to the tumor resection cavity with standard-of-care (SOC) versus SOC alone in participants with clinical stage II-III triple negative breast cancer (TNBC) undergoing breast-conserving surgery (BCS) who are neoadjuvant therapy naïve.
Conditions
- TNBC - Triple-Negative Breast Cancer
Interventions
BCS + SRG-514Drug
BCS + SRG-514
BCSProcedure
BCS
Primary outcomes
What the sponsor says the trial is designed to measure.
- EFS by BICR assessmentTime frame: EFS is defined as the time from randomization to the first occurrence of an event up to 5 years post BCS.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Mayo
Rochester, Minnesota
NYU Langone Health
New York, New York
Duke Cancer Center
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.